Mirum Pharmaceuticals (STU:08D) Accounts Payable: €51.4 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:08D Mirum Pharmaceuticals Inc STU:08D
49 GF Score
Price €101.80
GF Value €72.37
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Mirum Pharmaceuticals Accounts Payable?

Mirum Pharmaceuticals STU:08D +1.14% 49 Accounts Payable is €51.4 Mil as of Mar. 2026. GuruFocus rates STU:08D with a GF Score™ of 49/100 and a GF Value™ of €72.37 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Mirum Pharmaceuticals's Accounts Payable for the quarter that ended in Mar. 2026 was €51.4 Mil.

Mirum Pharmaceuticals's quarterly Accounts Payable declined from Sep. 2025 (€10.4 Mil) to Dec. 2025 (€8.2 Mil) but then increased from Dec. 2025 (€8.2 Mil) to Mar. 2026 (€51.4 Mil).

Mirum Pharmaceuticals's annual Accounts Payable increased from Dec. 2023 (€6.8 Mil) to Dec. 2024 (€14.0 Mil) but then declined from Dec. 2024 (€14.0 Mil) to Dec. 2025 (€8.2 Mil).

Mirum Pharmaceuticals Accounts Payable Related Terms

Mirum Pharmaceuticals Accounts Payable Historical Data

* Premium members only.

The historical data trend for Mirum Pharmaceuticals's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mirum Pharmaceuticals Accounts Payable Chart

Mirum Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 8.11 8.20 6.80 13.96 8.21

Mirum Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.77 15.31 10.37 8.21 51.38
STU:08D
49GF Score
Mirum Pharmaceuticals Inc STU:08D
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mirum Pharmaceuticals Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €51.4 Mil mean?
Mirum Pharmaceuticals (STU:08D) has a Accounts Payable of €51.4 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Mirum Pharmaceuticals and its competitors.
Is Mirum Pharmaceuticals' Accounts Payable too high?
Mirum Pharmaceuticals' current Accounts Payable is €51.4 Mil. Overall, Mirum Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mirum Pharmaceuticals' Accounts Payable compare to RYTM and SYRE?
Mirum Pharmaceuticals' Accounts Payable of €51.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Mirum Pharmaceuticals and its competitors. Mirum Pharmaceuticals's current Accounts Payable is €51.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mirum Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mirum Pharmaceuticals (STU:08D) is currently considered Significantly Overvalued. The stock's GF Value™ is €72.37, compared to a current price of €101.80 — trading 40.7% above its estimated fair value. The current Accounts Payable is €51.4 Mil. Mirum Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Mirum Pharmaceuticals (STU:08D), the current Accounts Payable is €51.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mirum Pharmaceuticals (STU:08D) Overvalued in 2026?

Based on GuruFocus' analysis, Mirum Pharmaceuticals stock appears to be overvalued. The current stock price of €101.80 is trading 40.7% above its estimated GF Value™ of €72.37. GuruFocus considers Mirum Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:08D:

  • Accounts Payable: €51.4 Mil
  • GF Value™: €72.37 vs. price of €101.80 (40.7% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the STU:08D stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mirum Pharmaceuticals Business Description

Other Exchanges MIRM:USA
Address 989 East Hillsdale Boulevard, Suite 300, Foster City, CA, USA, 94404
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
49GF Score

Get the complete analysis for STU:08D

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€101.80
Price
€72.37
GF Value